½ÃÀ庸°í¼­
»óǰÄÚµå
1150071

¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-½ÃÀå Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® : Ŭ·¡½ºº°, ¹æÃâ À¯Çüº°, Á¦Ç°º°, ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2022-2030³â)

Opioid Market Share, Size, Trends, Industry Analysis Report, By Class (Natural, Semi-synthetic, and fully synthetic); By Release Type; By Product; By Application; By Region; Segment Forecast, 2022 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 124 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 60¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ ¿ÀÇÇ¿ÀÀ̵å(Opioid) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä/½ÃÀå ±Ô¸ð ¹× ¿¹Ãø/µ¿Çâ/ÃËÁø ¿äÀΡ¤¾ïÁ¦ ¿äÀÎ/Ŭ·¡½ºº°¡¤¹æÃâ À¯Çüº°¡¤Á¦Ç°º°¡¤¿ëµµº°¡¤Áö¿ªº° ºÐ¼®/±â¾÷ °³¿ä µî Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

  • ¸®Æ÷Æ® ¼³¸í
    • Á¶»çÀÇ ¸ñÀû
    • ½ÃÀå ¹üÀ§
    • ÀüÁ¦ Á¶°Ç
  • ÀÌÇØ°ü°èÀÚ

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • °³¿ä
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
  • Á¤º¸¿ø
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸

Á¦4Àå ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå ÅëÂû

  • ¿ÀÇÇ¿ÀÀ̵å-»ê¾÷ ½º³À¼¦
  • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå ¿ªÇÐ
    • ÃËÁø ¿äÀΰú ±âȸ
    • ¾ïÁ¦ ¿äÀΰú °úÁ¦
  • Porter¡¯s Five Forces
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ½Å±Ô Âü°¡ÀÚÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • ´ëüǰÀÇ À§Çù
    • ±âÁ¸ ±â¾÷ °£ÀÇ °æÀï·Â
  • PESTLE ºÐ¼®
  • ¿ÀÇÇ¿ÀÀÌµå »ê¾÷ÀÇ µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19 ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå : Ŭ·¡½ºº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Ŭ·¡½ºº°(2018-2030³â)
  • õ¿¬
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, õ¿¬º°, Áö¿ªº°(2018-2030³â)
  • ¹ÝÇÕ¼º
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¹ÝÇÕ¼ºº°, Áö¿ªº°(2018-2030³â)
  • ¿ÏÀü ÇÕ¼º
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¿ÏÀü ÇÕ¼ºº°, Áö¿ªº°(2018-2030³â)

Á¦6Àå ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå : ¹æÃâ À¯Çüº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¹æÃâ À¯Çüº°(2018-2030³â)
  • Áï°¢ ¹æÃâÇü/´Ü½Ã°£ ÀÛ¿ëÇü ¿ÀÇÇ¿ÀÀ̵å
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Áï°¢ ¹æÃâÇü/´Ü½Ã°£ ÀÛ¿ëÇü ¿ÀÇÇ¿ÀÀ̵庰, Áö¿ªº°(2018-2030³â)
  • Áö¼Ó ¹æÃâÇü/Àå½Ã°£ ÀÛ¿ëÇü ¿ÀÇÇ¿ÀÀ̵å
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Áö¼Ó ¹æÃâÇü/Àå½Ã°£ ÀÛ¿ëÇü ¿ÀÇÇ¿ÀÀ̵庰, Áö¿ªº°(2018-2030³â)

Á¦7Àå ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå : Á¦Ç°º°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Á¦Ç°º°(2018-2030³â)
  • ÄÚµ¥ÀÎ
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ÄÚµ¥Àκ°, Áö¿ªº°(2018-2030³â)
  • ÆæÅ¸´Ò
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ÆæÅ¸´Òº°, Áö¿ªº°(2018-2030³â)
  • ¿Á½ÃÄÚµ·
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¿Á½ÃÄÚµ·º°, Áö¿ªº°(2018-2030³â)
  • ¸ÞŸµ·
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¸ÞŸµ·º°, Áö¿ªº°(2018-2030³â)
  • ¸ð¸£ÇÉ
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¸ð¸£Çɺ°, Áö¿ªº°(2018-2030³â)
  • È÷µå·ÎÄÚµ·
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, È÷µå·ÎÄÚµ·º°, Áö¿ªº°(2018-2030³â)
  • Æ®¶ó¸¶µ¹
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Æ®¶ó¸¶µ¹º°, Áö¿ªº°(2018-2030³â)
  • ÇÁ·ÎÆø½ÃÆæ
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ÇÁ·ÎÆø½ÃÆæº°, Áö¿ªº°(2018-2030³â)
  • ±âŸ
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ±âŸº°, Áö¿ªº°(2018-2030³â)

Á¦8Àå ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå : ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¿ëµµº°(2018-2030³â)
  • ÅëÁõ °ü¸®
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ÅëÁõ °ü¸®º°, Áö¿ªº°(2018-2030³â)
    • ½Å°æÀå¾Ö
    • ÆíµÎÅë
    • Á¤Çü¿Ü°ú¡¤±Ù°ñ°Ý
  • ¾Ï¼º ÅëÁõ
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¾Ï¼º ÅëÁõº°, Áö¿ªº°(2018-2030³â)
  • ³ú
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ³úº°, Áö¿ªº°(2018-2030³â)
    • ÈäºÎ
    • °áÀ塤Á÷Àå
    • Ç÷¾×
    • ÇǺÎ
    • Àü¸³¼±
    • ±âŸ
  • ±âħ Ä¡·á
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ±âħ Ä¡·áº°, Áö¿ªº°(2018-2030³â)
  • ÁøÅëÁ¦
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ÁøÅëÁ¦º°, Áö¿ªº°(2018-2030³â)
  • ¼³»ç Ä¡·á
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¼³»ç Ä¡·áº°, Áö¿ªº°(2018-2030³â)
  • Å»Áßµ¶
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Å»Áßµ¶º°, Áö¿ªº°(2018-2030³â)
  • ±âŸ
    • ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ±âŸº°, Áö¿ªº°(2018-2030³â)

Á¦9Àå ¼¼°èÀÇ ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀåÀÇ Æò°¡, Áö¿ªº°(2018-2030³â)
  • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-ºÏ¹Ì
    • ºÏ¹Ì : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Ŭ·¡½ºº°(2018-2030³â)
    • ºÏ¹Ì : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¿ëµµº°(2018-2030³â)
    • ºÏ¹Ì : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¹æÃâ À¯Çüº°(2018-2030³â)
    • ºÏ¹Ì : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-¹Ì±¹
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-ij³ª´Ù
  • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-À¯·´
    • À¯·´ : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Ŭ·¡½ºº°(2018-2030³â)
    • À¯·´ : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¿ëµµº°(2018-2030³â)
    • À¯·´ : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¹æÃâ À¯Çüº°(2018-2030³â)
    • À¯·´ : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-¿µ±¹
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-ÇÁ¶û½º
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-µ¶ÀÏ
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-ÀÌÅ»¸®¾Æ
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-½ºÆäÀÎ
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-³×´ú¶õµå
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-·¯½Ã¾Æ
  • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-¾Æ½Ã¾Æ ÅÂÆò¾ç
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Ŭ·¡½ºº°(2018-2030³â)
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¿ëµµº°(2018-2030³â)
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¹æÃâ À¯Çüº°(2018-2030³â)
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-Áß±¹
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-Àεµ
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-ÀϺ»
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-¸»·¹À̽þÆ
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-Àεµ³×½Ã¾Æ
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-Çѱ¹
  • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-Áßµ¿¡¤¾ÆÇÁ¸®Ä«
    • Áßµ¿¡¤¾ÆÇÁ¸®Ä« : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Ŭ·¡½ºº°(2018-2030³â)
    • Áßµ¿¡¤¾ÆÇÁ¸®Ä« : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¿ëµµº°(2018-2030³â)
    • Áßµ¿¡¤¾ÆÇÁ¸®Ä« : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¹æÃâ À¯Çüº°(2018-2030³â)
    • Áßµ¿¡¤¾ÆÇÁ¸®Ä« : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-»ç¿ìµð ¾Æ¶óºñ¾Æ
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-³²¾ÆÇÁ¸®Ä«
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-À̽º¶ó¿¤
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-¾Æ¶ø ¿¡¹Ì¸®Æ® ¿¬¹æ
  • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-³²¹Ì
    • ³²¹Ì : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Ŭ·¡½ºº°(2018-2030³â)
    • ³²¹Ì : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¿ëµµº°(2018-2030³â)
    • ³²¹Ì : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, ¹æÃâ À¯Çüº°(2018-2030³â)
    • ³²¹Ì : ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå, Á¦Ç°º°(2018-2030³â)
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-¸ß½ÃÄÚ
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-ºê¶óÁú
    • ¿ÀÇÇ¿ÀÀÌµå ½ÃÀå-¾Æ¸£ÇîÆ¼³ª

Á¦10Àå °æÀï »óȲ

  • È®´ë¡¤Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • ÆÄÆ®³Ê½Ê/Çù¾÷/ÇùÁ¤/Àü½Ã

Á¦11Àå ±â¾÷ °³¿ä

  • Aurobindo Pharma Limited,
  • Assertio Therapeutics, Inc.
  • AbbVie Inc.
  • Actavis Plc.
  • Amneal Pharmaceuticals LLC
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Limited
  • Fresenius Kabi
  • Mallinckrodt Pharmaceuticals
  • Endo International plc
  • IBM Corporation
  • Lupin Limited
  • Nesher Pharmaceuticals(USA) LLC
  • Purdue Pharma LP
  • Pfizer Inc.
  • Rhodes Pharmaceuticals LP
  • Sun Pharmaceutical Industries Limited
  • Trevena Inc.
  • Teva Pharmaceutical Industries Ltd.
LYJ 22.11.30

The global opioid market size is expected to reach USD 6.02 billion by 2030, according to a new study by Polaris Market Research. The report "Opioid Market Share, Size, Trends, Industry Analysis Report, By Class (Natural, Semi-synthetic, and Fully synthetic); By Release Type; By Product; By Application; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

An increase in the use of these medications to treat pain and an increase in the number of elderly people, who are particularly vulnerable to orthopedic pain, are the main reasons driving the market's expansion. Since chronic pain is widespread in the aged population and is thought to be a separate risk factor for mortality, the aging population is a significant driving force behind the industry's explosive expansion. For instance, the World Health Organization (WHO) projects that by 2050, there will be about 2.0 billion people in the world who are 60 years of age or older, with most of the growth occurring in developing nations. In 2015, there were approximately 900 million people in this age group. France has almost 150 years to adapt to a rise in the percentage of people over 60 from 10% to 20% of the population.

The elderly increasingly suffer from chronic diseases like diabetes due to the growing aging population and changing lifestyles driving demand for cutting-edge healthcare technologies. This has increased industry expansion. Asthma, diabetes, heart disease, cancer, and other conditions that persist for a long time and are frequently incurable are examples of chronic diseases. The three most prevalent medical diagnoses worldwide are asthma, diabetes, and heart disease.

The primary reasons behind the burgeoning chronic conditions are unhealthy lifestyles, alcohol consumption, smoking habits, and physical inactivity. Poverty is also one of the reasons for growth in long-term illness, particularly in underdeveloped regions of the world, such as African nations, Asian countries, and the countries of South America. These long-term illness conditions are the leading cause of disability and death worldwide. The significant population over 65 is reported to have long-term diseases because of irregular lifestyles. Thus, the demand for opioids among the aging population with chronic disease is growing, driving industry growth.

Additionally, there has been a marked increase in the number of persons worldwide who experience chronic pain. The market is expected to rise as a result, according to predictions. For instance, the Centers for Disease Control and Prevention (CDC) 2019 found that 7.4% of Americans had high-impact chronic pain.

Opioid Market Report Highlights

The long-acting opioids segment is anticipated to grow at the highest CAGR over the forecast period. These drugs are frequently used to treat moderate to severe chronic pain. These medications offer therapeutic advantages such as consistent, long-lasting analgesia and reduced dose frequency.

Semi-synthetic opioids segment accounted for to growth rapidly of the global revenue share due to the increased availability and demand for these painkillers. Labs use natural opiates to create semi-synthetic types.

Asia-Pacific is expected to grow prominently over the projected period. This can be attributed to cancer cases rising across several developing economies. Nearly half of cancer's worldwide burden is borne by Asia. Additionally, a growing elderly population and an increase in cases of chronic pain would increase regional market demand.

The global market is highly competitive owing to the existence of prominent players with a worldwide presence, including Aurobindo Pharma Limited, Assertio Therapeutics, Inc., AbbVie Inc., Nesher Pharmaceuticals (USA) LLC, Purdue Pharma L.P., Pfizer Inc., Rhodes Pharmaceuticals L.P., Sun Pharmaceutical Industries Limited, Trevena Inc., and Teva Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the Opioid market report based on class, release type, product, application, and region:

Opioid, Class Outlook (Revenue - USD Billion, 2018 - 2030)

Natural

Semi-synthetic

Fully Synthetic

Opioid, Release Type Outlook (Revenue - USD Billion, 2018 - 2030)

Immediate-release/Short-acting

Extended-release/Long-acting

Opioid, Product Outlook (Revenue - USD Billion, 2018 - 2030)

Codeine

Fentanyl

Oxycodone

Methadone

Morphine

Hydrocodone

Tramadol

Propoxyphene

Others

Opioid, Application Outlook (Revenue - USD Billion, 2018 - 2030)

Pain management

Neuropathic

Migraine

Orthopedic and Musculoskeletal

Arthritis

Fibromyalgia

Others

Cancer Pain

Brain

Breast

Colorectal

Blood

Skin

Prostate

Others

Others

Cough treatment

Analgesia

Diarrhea treatment

De-addiction

Others

Opioid, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Opioid Market Insights

  • 4.1. Opioid - Industry Snapshot
  • 4.2. Opioid Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Expanding application of opioids in various therapeutic conditions
      • 4.2.1.2. Expanding target audience for the opioid market
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Stringent regulatory framework
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Opioid Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Opioid Market, by Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Opioid Market, by Class, 2018 - 2030 (USD Billion)
  • 5.3. Natural
    • 5.3.1. Global Opioid Market, by Natural, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Semi-synthetic
    • 5.4.1. Global Opioid Market, by Semi-synthetic, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Fully synthetic
    • 5.5.1. Global Opioid Market, by Fully synthetic, by Region, 2018 - 2030 (USD Billion)

6. Global Opioid Market, by Release Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
  • 6.3. Immediate-release/Short-acting opioid
    • 6.3.1. Global Opioid Market, by Immediate-release/Short-acting opioid, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Extended-release/Long-acting opioid
    • 6.4.1. Global Opioid Market, by Extended-release/Long-acting opioid, by Region, 2018 - 2030 (USD Billion)

7. Global Opioid Market, by Product

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Opioid Market, by Product, 2018 - 2030 (USD Billion)
  • 7.3. Codeine
    • 7.3.1. Global Opioid Market, by Codeine, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Fentanyl
    • 7.4.1. Global Opioid Market, by Fentanyl, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Oxycodone
    • 7.5.1. Global Opioid Market, by Oxycodone, by Region, 2018 - 2030 (USD Billion)
  • 7.6. Methadone
    • 7.6.1. Global Opioid Market, by Methadone, by Region, 2018 - 2030 (USD Billion)
  • 7.7. Morphine
    • 7.7.1. Global Opioid Market, by Morphine, by Region, 2018 - 2030 (USD Billion)
  • 7.8. Hydrocodone
    • 7.8.1. Global Opioid Market, by Hydrocodone, by Region, 2018 - 2030 (USD Billion)
  • 7.9. Tramadol
    • 7.9.1. Global Opioid Market, by Tramadol, by Region, 2018 - 2030 (USD Billion)
  • 7.10. Propoxyphene
    • 7.10.1. Global Opioid Market, by Propoxyphene, by Region, 2018 - 2030 (USD Billion)
  • 7.11. Others
    • 7.11.1. Global Opioid Market, by Others, by Region, 2018 - 2030 (USD Billion)

8. Global Opioid Market, by Application

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Opioid Market, by Application, 2018 - 2030 (USD Billion)
  • 8.3. Pain management
    • 8.3.1. Global Opioid Market, by Pain management, by Region, 2018 - 2030 (USD Billion)
    • 8.3.2. Neuropathic
      • 8.3.2.1. Global Opioid Market, by Neuropathic, by Region, 2018 - 2030 (USD Billion)
    • 8.3.3. Migraine
      • 8.3.3.1. Global Opioid Market, by Migraine, by Region, 2018 - 2030 (USD Billion)
    • 8.3.4. Orthopedic and Musculoskeletal
      • 8.3.4.1. Global Opioid Market, by Orthopedic and Musculoskeletal, by Region, 2018 - 2030 (USD Billion)
      • 8.3.4.2. Arthritis
      • 8.3.4.2.1. Global Opioid Market, by Arthritis, by Region, 2018 - 2030 (USD Billion)
      • 8.3.4.3. Fibromyalgia
      • 8.3.4.3.1. Global Opioid Market, by Fibromyalgia, by Region, 2018 - 2030 (USD Billion)
      • 8.3.4.4. Others
      • 8.3.4.4.1. Global Opioid Market, by Others, by Region, 2018 - 2030 (USD Billion)
  • 8.4. Cancer Pain
    • 8.4.1. Global Opioid Market, by Cancer Pain, by Region, 2018 - 2030 (USD Billion)
  • 8.5. Brain
    • 8.5.1. Global Opioid Market, by Brain, by Region, 2018 - 2030 (USD Billion)
    • 8.5.2. Breast
      • 8.5.2.1. Global Opioid Market, by Breast, by Region, 2018 - 2030 (USD Billion)
    • 8.5.3. Colorectal
      • 8.5.3.1. Global Opioid Market, by Colorectal, by Region, 2018 - 2030 (USD Billion)
    • 8.5.4. Blood
      • 8.5.4.1. Global Opioid Market, by Blood, by Region, 2018 - 2030 (USD Billion)
    • 8.5.5. Skin
      • 8.5.5.1. Global Opioid Market, by Skin, by Region, 2018 - 2030 (USD Billion)
    • 8.5.6. Prostate
      • 8.5.6.1. Global Opioid Market, by Prostate, by Region, 2018 - 2030 (USD Billion)
    • 8.5.7. Others
      • 8.5.7.1. Global Opioid Market, by Others, by Region, 2018 - 2030 (USD Billion)
  • 8.6. Cough treatment
    • 8.6.1. Global Opioid Market, by Cough treatment, by Region, 2018 - 2030 (USD Billion)
  • 8.7. Analgesia
    • 8.7.1. Global Opioid Market, by Analgesia, by Region, 2018 - 2030 (USD Billion)
  • 8.8. Diarrhea treatment
    • 8.8.1. Global Opioid Market, by Diarrhea treatment, by Region, 2018 - 2030 (USD Billion)
  • 8.9. De-addiction
    • 8.9.1. Global Opioid Market, by De-addiction, by Region, 2018 - 2030 (USD Billion)
  • 8.10. Others
    • 8.10.1. Global Opioid Market, by Others, by Region, 2018 - 2030 (USD Billion)

9. Global Opioid Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Opioid Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 9.3. Opioid Market - North America
    • 9.3.1. North America: Opioid Market, by Class, 2018 - 2030 (USD Billion)
    • 9.3.2. North America: Opioid Market, by Application, 2018 - 2030 (USD Billion)
    • 9.3.3. North America: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
    • 9.3.4. North America: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.3.5. Opioid Market - U.S.
      • 9.3.5.1. U.S.: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.3.5.2. U.S.: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.3.5.3. U.S.: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.3.5.4. U.S.: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.3.6. Opioid Market - Canada
      • 9.3.6.1. Canada: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.3.6.2. Canada: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.3.6.3. Canada: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.3.6.4. Canada: Opioid Market, by Product, 2018 - 2030 (USD Billion)
  • 9.4. Opioid Market - Europe
    • 9.4.1. Europe: Opioid Market, by Class, 2018 - 2030 (USD Billion)
    • 9.4.2. Europe: Opioid Market, by Application, 2018 - 2030 (USD Billion)
    • 9.4.3. Europe: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
    • 9.4.4. Europe: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.5. Opioid Market - UK
      • 9.4.5.1. UK: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.4.5.2. UK: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.4.5.3. UK: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.4.5.4. UK: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.6. Opioid Market - France
      • 9.4.6.1. France: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.4.6.2. France: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.4.6.3. France: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.4.6.4. France: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.7. Opioid Market - Germany
      • 9.4.7.1. Germany: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.4.7.2. Germany: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.4.7.3. Germany: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.4.7.4. Germany: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.8. Opioid Market - Italy
      • 9.4.8.1. Italy: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.4.8.2. Italy: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.4.8.3. Italy: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.4.8.4. Italy: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.9. Opioid Market - Spain
      • 9.4.9.1. Spain: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.4.9.2. Spain: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.4.9.3. Spain: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.4.9.4. Spain: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.10. Opioid Market - Netherlands
      • 9.4.10.1. Netherlands: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.4.10.2. Netherlands: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.4.10.3. Netherlands: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.4.10.4. Netherlands: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.11. Opioid Market - Russia
      • 9.4.11.1. Russia: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.4.11.2. Russia.: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.4.11.3. Russia: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.4.11.4. Russia: Opioid Market, by Product, 2018 - 2030 (USD Billion)
  • 9.5. Opioid Market - Asia Pacific
    • 9.5.1. Asia Pacific: Opioid Market, by Class, 2018 - 2030 (USD Billion)
    • 9.5.2. Asia Pacific: Opioid Market, by Application, 2018 - 2030 (USD Billion)
    • 9.5.3. Asia Pacific: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
    • 9.5.4. Asia Pacific: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.5. Opioid Market - China
      • 9.5.5.1. China: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.5.5.2. China.: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.5.5.3. China: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.5.5.4. China: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.6. Opioid Market - India
      • 9.5.6.1. India: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.5.6.2. India.: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.5.6.3. India: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.5.6.4. India: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.7. Opioid Market - Japan
      • 9.5.7.1. Japan: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.5.7.2. Japan.: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.5.7.3. Japan: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.5.7.4. Japan: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.8. Opioid Market - Malaysia
      • 9.5.8.1. Malaysia: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.5.8.2. Malaysia.: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.5.8.3. Malaysia: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.5.8.4. Malaysia: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.9. Opioid Market - Indonesia
      • 9.5.9.1. Indonesia: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.5.9.2. Indonesia.: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.5.9.3. Indonesia: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.5.9.4. Indonesia: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.10. Opioid Market - South Korea
      • 9.5.10.1. South Korea: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.5.10.2. South Korea.: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.5.10.3. South Korea: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.5.10.4. South Korea: Opioid Market, by Product, 2018 - 2030 (USD Billion)
  • 9.6. Opioid Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Opioid Market, by Class, 2018 - 2030 (USD Billion)
    • 9.6.2. Middle East & Africa: Opioid Market, by Application, 2018 - 2030 (USD Billion)
    • 9.6.3. Middle East & Africa: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
    • 9.6.4. Middle East & Africa: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.6.5. Opioid Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.6.6. Opioid Market - South Africa
      • 9.6.6.1. South Africa: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.6.6.2. South Africa: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.6.6.3. South Africa: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.6.6.4. South Africa: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.6.7. Opioid Market - Israel
      • 9.6.7.1. Israel: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.6.7.2. Israel: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.6.7.3. Israel: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.6.7.4. Israel: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.6.8. Opioid Market - UAE
      • 9.6.8.1. UAE: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.6.8.2. UAE: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.6.8.3. UAE: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.6.8.4. UAE: Opioid Market, by Product, 2018 - 2030 (USD Billion)
  • 9.7. Opioid Market - Latin America
    • 9.7.1. Latin America: Opioid Market, by Class, 2018 - 2030 (USD Billion)
    • 9.7.2. Latin America: Opioid Market, by Application, 2018 - 2030 (USD Billion)
    • 9.7.3. Latin America: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
    • 9.7.4. Latin America: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.7.5. Opioid Market - Mexico
      • 9.7.5.1. Mexico: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.7.5.2. Mexico: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.7.5.3. Mexico: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.7.5.4. Mexico: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.7.6. Opioid Market - Brazil
      • 9.7.6.1. Brazil: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.7.6.2. Brazil: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.7.6.3. Brazil: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.7.6.4. Brazil: Opioid Market, by Product, 2018 - 2030 (USD Billion)
    • 9.7.7. Opioid Market - Argentina
      • 9.7.7.1. Argentina: Opioid Market, by Class, 2018 - 2030 (USD Billion)
      • 9.7.7.2. Argentina: Opioid Market, by Application, 2018 - 2030 (USD Billion)
      • 9.7.7.3. Argentina: Opioid Market, by Release Type, 2018 - 2030 (USD Billion)
      • 9.7.7.4. Argentina: Opioid Market, by Product, 2018 - 2030 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Aurobindo Pharma Limited,
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Assertio Therapeutics, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. AbbVie Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Actavis Plc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Amneal Pharmaceuticals LLC
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Boehringer Ingelheim International GmbH
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Cadila Healthcare Limited
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Fresenius Kabi
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Mallinckrodt Pharmaceuticals
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Endo International plc
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. IBM Corporation
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Lupin Limited
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Nesher Pharmaceuticals (USA) LLC
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Purdue Pharma L.P.
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Pfizer Inc.
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. Rhodes Pharmaceuticals L.P.
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
  • 11.17. Sun Pharmaceutical Industries Limited
    • 11.17.1. Company Overview
    • 11.17.2. Financial Performance
    • 11.17.3. Product Benchmarking
    • 11.17.4. Recent Development
  • 11.18. Trevena Inc.
    • 11.18.1. Company Overview
    • 11.18.2. Financial Performance
    • 11.18.3. Product Benchmarking
    • 11.18.4. Recent Development
  • 11.19. Teva Pharmaceutical Industries Ltd.
    • 11.19.1. Company Overview
    • 11.19.2. Financial Performance
    • 11.19.3. Product Benchmarking
    • 11.19.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦